HUMAN:APOE

From GONUTS

Jump to: navigation, search

Species (Taxon ID)	Homo sapiens (Human). (taxon:9606)
Gene Name(s)	APOE
Protein Name(s)	Apolipoprotein E Apo-E
External Links
UniProt Identifier	APOE_HUMAN
UniProt Accessions	P02649, B2RC15, C0JYY5, Q9P2S4,
EMBL	M12529, K00396, M10065, AF050154, AF261279, AK314898, FJ525876, BC003557, AB035149,
PIR	A92478,
RefSeq	NP_000032.1,
PDB	1B68, 1BZ4, 1EA8, 1GS9, 1H7I, 1LE2, 1LE4, 1LPE, 1NFN, 1NFO, 1OEF, 1OEG, 1OR2, 1OR3, 2KC3, 2KNY,
IntAct	P02649,
Ensembl	ENST00000252486,
Pfam	PF01442,

Annotations

Qualifier	GO ID	GO term name	Reference	Evidence Code	with/from	Aspect	Notes	Status
	GO:0043025	cell soma		NAS: Non-traceable Author Statement		C	Source: UniProtKB
	GO:0042627	chylomicron		IEA		C	Source: UniProtKB-KW
	GO:0030425	dendrite		NAS: Non-traceable Author Statement		C	Source: UniProtKB
	GO:0034364	high-density lipoprotein particle		IEA		C	Source: UniProtKB-KW
	GO:0034363	intermediate-density lipoprotein particle		IDA: Inferred from Direct Assay		C	Source: UniProtKB
	GO:0034362	low-density lipoprotein particle		IDA: Inferred from Direct Assay		C	Source: UniProtKB
	GO:0034361	very-low-density lipoprotein particle		IEA		C	Source: UniProtKB-KW
	GO:0016209	antioxidant activity		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0001540	beta-amyloid binding		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0008201	heparin binding		IEA		F	Source: UniProtKB-KW
	GO:0050750	low-density lipoprotein receptor binding		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0046911	metal chelating activity		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0005543	phospholipid binding		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0046982	protein heterodimerization activity		IPI: Inferred from Physical Interaction		F	Source: UniProtKB
	GO:0042803	protein homodimerization activity		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0048156	tau protein binding		IPI: Inferred from Physical Interaction		F	Source: UniProtKB
	GO:0070326	very-low-density lipoprotein receptor binding		IDA: Inferred from Direct Assay		F	Source: UniProtKB
	GO:0033344	cholesterol efflux		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0042632	cholesterol homeostasis		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0034382	chylomicron remnant clearance		IMP: Inferred from Mutant Phenotype		P	Source: UniProtKB
	GO:0046907	intracellular transport		TAS: Traceable Author Statement		P	Source: UniProtKB
	GO:0010875	positive regulation of cholesterol efflux		IDA: Inferred from Direct Assay		P		required field missing
	GO:0033700	phospholipid efflux		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0032805	positive regulation of low-density lipoprot...		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0045541	negative regulation of cholesterol biosynthetic process		IDA: Inferred from Direct Assay		P		required field missing
	GO:0034375	high-density lipoprotein particle remodeling		IGI: Inferred from Genetic Interaction		P		required field missing
	GO:0034380	high-density lipoprotein particle assembly		IDA: Inferred from Direct Assay		P		required field missing
	GO:0006898	receptor-mediated endocytosis		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0034384	high-density lipoprotein particle clearance		IDA: Inferred from Direct Assay		P		required field missing
	GO:0010873	positive regulation of cholesterol esterification		IMP: Inferred from Mutant Phenotype		P		required field missing
	GO:0008203	cholesterol metabolic process		IMP: Inferred from Mutant Phenotype		P		required field missing
	GO:0034372	very-low-density lipoprotein particle remodeling		IGI: Inferred from Genetic Interaction		P		required field missing
	GO:0043691	reverse cholesterol transport		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0006641	triglyceride metabolic process		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0034447	very-low-density lipoprotein particle clear...		IDA: Inferred from Direct Assay		P	Source: UniProtKB
	GO:0000302	response to reactive oxygen species	PMID:11743999^[1]	NAS: Non-traceable Author Statement		P
	GO:0001540	beta-amyloid binding	PMID:11305869^[2]	IDA: Inferred from Direct Assay		F
	GO:0001937	negative regulation of endothelial cell proliferation	PMID:9685360^[3]	IDA: Inferred from Direct Assay		P
	GO:0002021	response to dietary excess	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0005319	lipid transporter activity	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	F
	GO:0005319	lipid transporter activity	PMID:17305370^[4]	IDA: Inferred from Direct Assay		F
	GO:0005515	protein binding	PMID:21163940^[5]	IPI: Inferred from Physical Interaction	UniProtKB:P50502	F
	GO:0005515	protein binding	PMID:21163940^[5]	IPI: Inferred from Physical Interaction	UniProtKB:Q16543	F
	GO:0005515	protein binding	PMID:21163940^[5]	IPI: Inferred from Physical Interaction	UniProtKB:Q53EL6	F
	GO:0005515	protein binding	PMID:21163940^[5]	IPI: Inferred from Physical Interaction	UniProtKB:Q9BQ95	F
	GO:0005515	protein binding	PMID:21593558^[6]	IPI: Inferred from Physical Interaction	UniProtKB:O75069	F
	GO:0005515	protein binding	PMID:7972031^[7]	IPI: Inferred from Physical Interaction	UniProtKB:P10636	F
	GO:0005543	phospholipid binding	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	F
	GO:0005543	phospholipid binding	PMID:4066713^[8]	IDA: Inferred from Direct Assay		F
	GO:0005576	extracellular region	GO_REF:0000002	IEA: Inferred from Electronic Annotation	InterPro:IPR000074	C
	GO:0005576	extracellular region	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0964	C
	GO:0005576	extracellular region	GO_REF:0000023	IEA: Inferred from Electronic Annotation	SP_SL:SL-0243	C
	GO:0005576	extracellular region	Reactome:REACT_13783	TAS: Traceable Author Statement		C
	GO:0005576	extracellular region	Reactome:REACT_6727	TAS: Traceable Author Statement		C
	GO:0005576	extracellular region	Reactome:REACT_6734	TAS: Traceable Author Statement		C
	GO:0005576	extracellular region	Reactome:REACT_6849	TAS: Traceable Author Statement		C
	GO:0005576	extracellular region	Reactome:REACT_6852	TAS: Traceable Author Statement		C
	GO:0005576	extracellular region	Reactome:REACT_6865	TAS: Traceable Author Statement		C
	GO:0005615	extracellular space	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	C
	GO:0005615	extracellular space	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005615	extracellular space	PMID:20551380^[9]	IDA: Inferred from Direct Assay		C
	GO:0005737	cytoplasm	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005737	cytoplasm	PMID:8083695^[10]	NAS: Non-traceable Author Statement		C
	GO:0005737	cytoplasm	PMID:9622609^[11]	TAS: Traceable Author Statement		C
	GO:0005769	early endosome	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005770	late endosome	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005794	Golgi apparatus	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005874	microtubule	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0005886	plasma membrane	Reactome:REACT_6849	TAS: Traceable Author Statement		C
	GO:0006629	lipid metabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0006629	lipid metabolic process	Reactome:REACT_602	TAS: Traceable Author Statement		P
	GO:0006641	triglyceride metabolic process	PMID:3771793^[12]	IMP: Inferred from Mutant Phenotype		P
	GO:0006641	triglyceride metabolic process	PMID:9649566^[13]	IDA: Inferred from Direct Assay		P
	GO:0006707	cholesterol catabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0006810	transport	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0813	P
	GO:0006869	lipid transport	GO_REF:0000002	IEA: Inferred from Electronic Annotation	InterPro:IPR000074	P
	GO:0006869	lipid transport	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0445	P
	GO:0006869	lipid transport	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0006874	cellular calcium ion homeostasis	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0006898	receptor-mediated endocytosis	PMID:1917954^[14]	IDA: Inferred from Direct Assay		P
	GO:0006916	anti-apoptosis	PMID:9685360^[3]	IDA: Inferred from Direct Assay		P
	GO:0006917	induction of apoptosis	PMID:12753088^[15]	IDA: Inferred from Direct Assay		P
	GO:0006979	response to oxidative stress	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0007010	cytoskeleton organization	PMID:9622609^[11]	TAS: Traceable Author Statement		P
	GO:0007186	G-protein coupled receptor protein signaling pathway	PMID:16443932^[16]	IDA: Inferred from Direct Assay		P
	GO:0007263	nitric oxide mediated signal transduction	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0007271	synaptic transmission, cholinergic	PMID:9622609^[11]	TAS: Traceable Author Statement		P
	GO:0007568	aging	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0008201	heparin binding	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0358	F
	GO:0008201	heparin binding	PMID:2745454^[18]	IDA: Inferred from Direct Assay		F
	GO:0008203	cholesterol metabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0008203	cholesterol metabolic process	PMID:3771793^[12]	IMP: Inferred from Mutant Phenotype		P
	GO:0008203	cholesterol metabolic process	PMID:9649566^[13]	IDA: Inferred from Direct Assay		P
	GO:0008219	cell death	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0523	P
	GO:0008289	lipid binding	GO_REF:0000002	IEA: Inferred from Electronic Annotation	InterPro:IPR000074	F
	GO:0008289	lipid binding	PMID:4066713^[8]	IDA: Inferred from Direct Assay		F
	GO:0010468	regulation of gene expression	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0010544	negative regulation of platelet activation	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0010873	positive regulation of cholesterol esterification	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0010873	positive regulation of cholesterol esterification	PMID:15654758^[19]	IDA: Inferred from Direct Assay		P
	GO:0010875	positive regulation of cholesterol efflux	PMID:12401887^[20]	IGI: Inferred from Genetic Interaction	UniProtKB:P08226	P
	GO:0010875	positive regulation of cholesterol efflux	PMID:14754908^[21]	IDA: Inferred from Direct Assay		P
	GO:0014012	peripheral nervous system axon regeneration	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0016209	antioxidant activity	PMID:9685360^[3]	IDA: Inferred from Direct Assay		F
	GO:0017127	cholesterol transporter activity	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	F
	GO:0019934	cGMP-mediated signaling	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0030195	negative regulation of blood coagulation	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0030425	dendrite	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0030425	dendrite	PMID:8083695^[10]	NAS: Non-traceable Author Statement		C
	GO:0030516	regulation of axon extension	PMID:9622609^[11]	TAS: Traceable Author Statement		P
	GO:0030828	positive regulation of cGMP biosynthetic process	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0031232	extrinsic to external side of plasma membrane	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0032488	Cdc42 protein signal transduction	PMID:16443932^[16]	IDA: Inferred from Direct Assay		P
	GO:0032805	positive regulation of low-density lipoprotein particle receptor catabolic process	PMID:15950758^[22]	IDA: Inferred from Direct Assay		P
	GO:0033344	cholesterol efflux	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0033344	cholesterol efflux	PMID:11162594^[23]	IDA: Inferred from Direct Assay		P
	GO:0033344	cholesterol efflux	PMID:16443932^[16]	IDA: Inferred from Direct Assay		P
	GO:0033700	phospholipid efflux	PMID:11162594^[23]	IDA: Inferred from Direct Assay		P
	GO:0034361	very-low-density lipoprotein particle	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0850	C
	GO:0034361	very-low-density lipoprotein particle	PMID:17154273^[24]	IDA: Inferred from Direct Assay		C
	GO:0034361	very-low-density lipoprotein particle	PMID:8245722^[25]	IDA: Inferred from Direct Assay		C
	GO:0034362	low-density lipoprotein particle	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	C
	GO:0034362	low-density lipoprotein particle	PMID:8245722^[25]	IDA: Inferred from Direct Assay		C
	GO:0034363	intermediate-density lipoprotein particle	PMID:17336988^[26]	IDA: Inferred from Direct Assay		C
	GO:0034364	high-density lipoprotein particle	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0345	C
	GO:0034364	high-density lipoprotein particle	PMID:210174^[27]	IDA: Inferred from Direct Assay		C
	GO:0034372	very-low-density lipoprotein particle remodeling	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0034372	very-low-density lipoprotein particle remodeling	PMID:12401887^[20]	IGI: Inferred from Genetic Interaction	UniProtKB:P08226	P
	GO:0034372	very-low-density lipoprotein particle remodeling	PMID:15654758^[19]	IDA: Inferred from Direct Assay		P
	GO:0034374	low-density lipoprotein particle remodeling	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0034375	high-density lipoprotein particle remodeling	PMID:12401887^[20]	IGI: Inferred from Genetic Interaction	UniProtKB:P08226	P
	GO:0034380	high-density lipoprotein particle assembly	PMID:17305370^[4]	IDA: Inferred from Direct Assay		P
	GO:0034382	chylomicron remnant clearance	PMID:7175379^[28]	IMP: Inferred from Mutant Phenotype		P
	GO:0034384	high-density lipoprotein particle clearance	PMID:210175^[29]	IDA: Inferred from Direct Assay		P
	GO:0034447	very-low-density lipoprotein particle clearance	PMID:1917954^[14]	IDA: Inferred from Direct Assay		P
	GO:0034447	very-low-density lipoprotein particle clearance	PMID:9649566^[13]	IMP: Inferred from Mutant Phenotype		P
	GO:0042157	lipoprotein metabolic process	GO_REF:0000002	IEA: Inferred from Electronic Annotation	InterPro:IPR000074	P
	GO:0042157	lipoprotein metabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0042157	lipoprotein metabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0042157	lipoprotein metabolic process	Reactome:REACT_13621	TAS: Traceable Author Statement		P
	GO:0042157	lipoprotein metabolic process	Reactome:REACT_6823	TAS: Traceable Author Statement		P
	GO:0042157	lipoprotein metabolic process	Reactome:REACT_6841	TAS: Traceable Author Statement		P
	GO:0042158	lipoprotein biosynthetic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0042159	lipoprotein catabolic process	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0042311	vasodilation	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0042627	chylomicron	GO_REF:0000004	IEA: Inferred from Electronic Annotation	SP_KW:KW-0162	C
	GO:0042627	chylomicron	PMID:16935699^[30]	IDA: Inferred from Direct Assay		C
	GO:0042627	chylomicron	PMID:8245722^[25]	IDA: Inferred from Direct Assay		C
	GO:0042632	cholesterol homeostasis	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0042632	cholesterol homeostasis	PMID:9649566^[13]	IDA: Inferred from Direct Assay		P
	GO:0042802	identical protein binding	PMID:4066713^[8]	IDA: Inferred from Direct Assay		F
	GO:0042803	protein homodimerization activity	PMID:8245722^[25]	IDA: Inferred from Direct Assay		F
	GO:0043025	neuronal cell body	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	C
	GO:0043025	neuronal cell body	PMID:8083695^[10]	NAS: Non-traceable Author Statement		C
	GO:0043407	negative regulation of MAP kinase activity	PMID:9685360^[3]	IDA: Inferred from Direct Assay		P
	GO:0043537	negative regulation of blood vessel endothelial cell migration	PMID:9685360^[3]	IDA: Inferred from Direct Assay		P
	GO:0043691	reverse cholesterol transport	PMID:8127890^[31]	IDA: Inferred from Direct Assay		P
	GO:0045471	response to ethanol	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0045541	negative regulation of cholesterol biosynthetic process	PMID:1917954^[14]	IDA: Inferred from Direct Assay		P
	GO:0046907	intracellular transport	PMID:9622609^[11]	TAS: Traceable Author Statement		P
	GO:0046911	metal chelating activity	PMID:9685360^[3]	IDA: Inferred from Direct Assay		F
	GO:0046982	protein heterodimerization activity	PMID:8245722^[25]	IPI: Inferred from Physical Interaction	UniProtKB:P02652	F
	GO:0048156	tau protein binding	PMID:7566652^[32]	IPI: Inferred from Physical Interaction	UniProtKB:P10636	F
	GO:0048168	regulation of neuronal synaptic plasticity	PMID:9622609^[11]	TAS: Traceable Author Statement		P
	GO:0048844	artery morphogenesis	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0050728	negative regulation of inflammatory response	PMID:8995232^[17]	IC: Inferred by Curator	GO:0051000	P
	GO:0050750	low-density lipoprotein particle receptor binding	PMID:17326667^[33]	IPI: Inferred from Physical Interaction	UniProtKB:Q92673	F
	GO:0050750	low-density lipoprotein particle receptor binding	PMID:210175^[29]	IDA: Inferred from Direct Assay		F
	GO:0051000	positive regulation of nitric-oxide synthase activity	PMID:8995232^[17]	IDA: Inferred from Direct Assay		P
	GO:0051044	positive regulation of membrane protein ectodomain proteolysis	PMID:15950758^[22]	IDA: Inferred from Direct Assay		P
	GO:0051651	maintenance of location in cell	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0055088	lipid homeostasis	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
	GO:0060228	phosphatidylcholine-sterol O-acyltransferase activator activity	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	F
	GO:0060228	phosphatidylcholine-sterol O-acyltransferase activator activity	PMID:15654758^[19]	IDA: Inferred from Direct Assay		F
	GO:0070326	very-low-density lipoprotein particle receptor binding	PMID:12950167^[34]	IPI: Inferred from Physical Interaction	UniProtKB:Q14114	F
	GO:0070326	very-low-density lipoprotein particle receptor binding	PMID:1384047^[35]	IDA: Inferred from Direct Assay		F
	GO:0071363	cellular response to growth factor stimulus	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSRNOP00000050968	P
	GO:0071813	lipoprotein particle binding	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	F
	GO:0072358	cardiovascular system development	GO_REF:0000019	IEA: Inferred from Electronic Annotation	Ensembl:ENSMUSP00000003066	P
edit table

Notes

References

See Help:References for how to manage references in GONUTS.

↑ Lauderback CM et al. (2002) Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 924: 90-7 PubMed GONUTS page
↑ Cho HS et al. (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60: 342-9 PubMed GONUTS page
↑ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Ishigami M et al. (1998) Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 273: 20156-61 PubMed GONUTS page
↑ ^4.0 ^4.1 Vedhachalam C et al. (2007) The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 46: 2583-93 PubMed GONUTS page
↑ ^5.0 ^5.1 ^5.2 ^5.3 Soler-López M et al. (2011) Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res 21: 364-76 PubMed GONUTS page
↑ Hopkins PC et al. (2011) The Impact of a Novel Apolipoprotein E and Amyloid-β Protein Precursor-Interacting Protein on the Production of Amyloid-β J Alzheimers Dis PubMed GONUTS page
↑ Strittmatter WJ et al. (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A 91: 11183-6 PubMed GONUTS page
↑ ^8.0 ^8.1 ^8.2 Yokoyama S et al. (1985) Behavior of human apolipoprotein E in aqueous solutions and at interfaces. J Biol Chem 260: 16375-82 PubMed GONUTS page
↑ Didangelos A et al. (2010) Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 9: 2048-62 PubMed GONUTS page
↑ ^10.0 ^10.1 ^10.2 Han SH et al. (1994) Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol 53: 535-44 PubMed GONUTS page
↑ ^11.0 ^11.1 ^11.2 ^11.3 ^11.4 ^11.5 Beffert U et al. (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Brain Res Rev 27: 119-42 PubMed GONUTS page
↑ ^12.0 ^12.1 Schaefer EJ et al. (1986) Familial apolipoprotein E deficiency. J Clin Invest 78: 1206-19 PubMed GONUTS page
↑ ^13.0 ^13.1 ^13.2 ^13.3 Sullivan PM et al. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102: 130-5 PubMed GONUTS page
↑ ^14.0 ^14.1 ^14.2 Sehayek E & Eisenberg S (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266: 18259-67 PubMed GONUTS page
↑ Eugenin EA et al. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 85: 1299-311 PubMed GONUTS page
↑ ^16.0 ^16.1 ^16.2 Nofer JR et al. (2006) Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res 47: 794-803 PubMed GONUTS page
↑ ^17.0 ^17.1 ^17.2 ^17.3 ^17.4 ^17.5 ^17.6 Riddell DR et al. (1997) Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 272: 89-95 PubMed GONUTS page
↑ Fielding PE et al. (1989) Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding. J Biol Chem 264: 12462-6 PubMed GONUTS page
↑ ^19.0 ^19.1 ^19.2 Zhao Y et al. (2005) Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry 44: 1013-25 PubMed GONUTS page
↑ ^20.0 ^20.1 ^20.2 Hopkins PC et al. (2002) Evidence for differential effects of apoE3 and apoE4 on HDL metabolism. J Lipid Res 43: 1881-9 PubMed GONUTS page
↑ Krimbou L et al. (2004) Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res 45: 839-48 PubMed GONUTS page
↑ ^22.0 ^22.1 Hoe HS & Rebeck GW (2005) Regulation of ApoE receptor proteolysis by ligand binding. Brain Res Mol Brain Res 137: 31-9 PubMed GONUTS page
↑ ^23.0 ^23.1 Remaley AT et al. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 280: 818-23 PubMed GONUTS page
↑ Mancone C et al. (2007) Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF. Proteomics 7: 143-54 PubMed GONUTS page
↑ ^25.0 ^25.1 ^25.2 ^25.3 ^25.4 Connelly PW et al. (1993) Identification of disulfide-linked apolipoprotein species in human lipoproteins. J Lipid Res 34: 1717-27 PubMed GONUTS page
↑ Meyer BJ et al. (2007) Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis 195: e28-34 PubMed GONUTS page
↑ Weisgraber KH & Mahley RW (1978) Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem 253: 6281-8 PubMed GONUTS page
↑ Breslow JL et al. (1982) Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 23: 1224-35 PubMed GONUTS page
↑ ^29.0 ^29.1 Innerarity TL et al. (1978) Apoprotein (E--A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E--A-II) complex. J Biol Chem 253: 6289-95 PubMed GONUTS page
↑ Jackson KG et al. (2006) Apolipoprotein E enrichment of immuno-separated chylomicron and chylomicron remnants following saturated fatty acids. Nutr Metab Cardiovasc Dis 16: 405-17 PubMed GONUTS page
↑ Huang Y et al. (1994) A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A 91: 1834-8 PubMed GONUTS page
↑ Huang DY et al. (1995) ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett 192: 209-12 PubMed GONUTS page
↑ Nilsson SK et al. (2007) Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46: 3896-904 PubMed GONUTS page
↑ Li X et al. (2003) Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry 42: 10406-17 PubMed GONUTS page
↑ Takahashi S et al. (1992) Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 89: 9252-6 PubMed GONUTS page

[PMID:11743999-0] Lauderback CM et al. (2002) Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 924: 90-7 PubMed GONUTS page

[PMID:11305869-1] Cho HS et al. (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60: 342-9 PubMed GONUTS page

[PMID:9685360-2] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Ishigami M et al. (1998) Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 273: 20156-61 PubMed GONUTS page

[PMID:17305370-3] 4.0 ^4.1 Vedhachalam C et al. (2007) The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 46: 2583-93 PubMed GONUTS page

[PMID:21163940-4] 5.0 ^5.1 ^5.2 ^5.3 Soler-López M et al. (2011) Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res 21: 364-76 PubMed GONUTS page

[PMID:21593558-5] Hopkins PC et al. (2011) The Impact of a Novel Apolipoprotein E and Amyloid-β Protein Precursor-Interacting Protein on the Production of Amyloid-β J Alzheimers Dis PubMed GONUTS page

[PMID:7972031-6] Strittmatter WJ et al. (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A 91: 11183-6 PubMed GONUTS page

[PMID:4066713-7] 8.0 ^8.1 ^8.2 Yokoyama S et al. (1985) Behavior of human apolipoprotein E in aqueous solutions and at interfaces. J Biol Chem 260: 16375-82 PubMed GONUTS page

[PMID:20551380-8] Didangelos A et al. (2010) Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 9: 2048-62 PubMed GONUTS page

[PMID:8083695-9] 10.0 ^10.1 ^10.2 Han SH et al. (1994) Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol 53: 535-44 PubMed GONUTS page

[PMID:9622609-10] 11.0 ^11.1 ^11.2 ^11.3 ^11.4 ^11.5 Beffert U et al. (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Brain Res Rev 27: 119-42 PubMed GONUTS page

[PMID:3771793-11] 12.0 ^12.1 Schaefer EJ et al. (1986) Familial apolipoprotein E deficiency. J Clin Invest 78: 1206-19 PubMed GONUTS page

[PMID:9649566-12] 13.0 ^13.1 ^13.2 ^13.3 Sullivan PM et al. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102: 130-5 PubMed GONUTS page

[PMID:1917954-13] 14.0 ^14.1 ^14.2 Sehayek E & Eisenberg S (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266: 18259-67 PubMed GONUTS page

[PMID:12753088-14] Eugenin EA et al. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 85: 1299-311 PubMed GONUTS page

[PMID:16443932-15] 16.0 ^16.1 ^16.2 Nofer JR et al. (2006) Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res 47: 794-803 PubMed GONUTS page

[PMID:8995232-16] 17.0 ^17.1 ^17.2 ^17.3 ^17.4 ^17.5 ^17.6 Riddell DR et al. (1997) Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 272: 89-95 PubMed GONUTS page

[PMID:2745454-17] Fielding PE et al. (1989) Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding. J Biol Chem 264: 12462-6 PubMed GONUTS page

[PMID:15654758-18] 19.0 ^19.1 ^19.2 Zhao Y et al. (2005) Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry 44: 1013-25 PubMed GONUTS page

[PMID:12401887-19] 20.0 ^20.1 ^20.2 Hopkins PC et al. (2002) Evidence for differential effects of apoE3 and apoE4 on HDL metabolism. J Lipid Res 43: 1881-9 PubMed GONUTS page

[PMID:14754908-20] Krimbou L et al. (2004) Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res 45: 839-48 PubMed GONUTS page

[PMID:15950758-21] 22.0 ^22.1 Hoe HS & Rebeck GW (2005) Regulation of ApoE receptor proteolysis by ligand binding. Brain Res Mol Brain Res 137: 31-9 PubMed GONUTS page

[PMID:11162594-22] 23.0 ^23.1 Remaley AT et al. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 280: 818-23 PubMed GONUTS page

[PMID:17154273-23] Mancone C et al. (2007) Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF. Proteomics 7: 143-54 PubMed GONUTS page

[PMID:8245722-24] 25.0 ^25.1 ^25.2 ^25.3 ^25.4 Connelly PW et al. (1993) Identification of disulfide-linked apolipoprotein species in human lipoproteins. J Lipid Res 34: 1717-27 PubMed GONUTS page

[PMID:17336988-25] Meyer BJ et al. (2007) Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis 195: e28-34 PubMed GONUTS page

[PMID:210174-26] Weisgraber KH & Mahley RW (1978) Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem 253: 6281-8 PubMed GONUTS page

[PMID:7175379-27] Breslow JL et al. (1982) Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 23: 1224-35 PubMed GONUTS page

[PMID:210175-28] 29.0 ^29.1 Innerarity TL et al. (1978) Apoprotein (E--A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E--A-II) complex. J Biol Chem 253: 6289-95 PubMed GONUTS page

[PMID:16935699-29] Jackson KG et al. (2006) Apolipoprotein E enrichment of immuno-separated chylomicron and chylomicron remnants following saturated fatty acids. Nutr Metab Cardiovasc Dis 16: 405-17 PubMed GONUTS page

[PMID:8127890-30] Huang Y et al. (1994) A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A 91: 1834-8 PubMed GONUTS page

[PMID:7566652-31] Huang DY et al. (1995) ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett 192: 209-12 PubMed GONUTS page

[PMID:17326667-32] Nilsson SK et al. (2007) Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46: 3896-904 PubMed GONUTS page

[PMID:12950167-33] Li X et al. (2003) Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry 42: 10406-17 PubMed GONUTS page

[PMID:1384047-34] Takahashi S et al. (1992) Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 89: 9252-6 PubMed GONUTS page

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

HUMAN:APOE

Contents

Annotations

Notes

References

a

b

c

d

e

g

h

h cont.

i

l

m

n

p

r

s

t

v

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Cacao

Journal Clubs

page contributors

Toolbox